CBC Group

Weijian Shan, the firm's Co-Founder and Chairman, chairs the investment committee and holds final decision-making authority on new commitments. Shan's four decades in private equity — spanning TPG, Newbridge Capital, and his academic career — make him the central figure in both origination and approval. The committee includes senior partners with operating and clinical expertise.

No. CBC Group is structurally a healthcare-only investment firm. Its mandate covers pharmaceuticals, biotechnology, medical devices, healthcare services, and related health-tech businesses, exclusively. The firm does not opportunistically pursue deals in consumer, industrials, or technology sectors.

CBC relies on a combination of deep government and regulatory relationships, an in-house team of clinical advisors who track drug-approval pipelines, and a network of hospital-group founders built over two decades by Weijian Shan. The firm also uses its operating-partner bench to identify roll-up targets inside fragmented sub-sectors like specialty pharmacy and in-vitro diagnostics.

The firm typically holds portfolio companies for five to seven years, consistent with classic buyout and growth-equity time horizons. Exits include strategic sales to multinational pharmaceutical or medtech companies seeking Asia distribution, IPOs on the Hong Kong or Shanghai exchanges, and secondary buyouts to other private equity firms building healthcare clusters.

Yes. CBC has a dedicated credit arm, the CBC Credit Opportunities Fund, which provides structured debt financing to healthcare companies across Asia. This vehicle allows the firm to participate in the capital structures of companies where it may or may not hold equity, and to deepen relationships with management teams ahead of potential control transactions.

CBC raises capital from global institutional limited partners, including North American and European pension funds, sovereign wealth funds, endowments, and family offices. The firm does not manage a single family's wealth, distinguishing it from a family-office structure. Capital is pooled into blind-pool drawdown funds with a standard private-equity fee and carry structure.

R-Bridge Healthcare serves as CBC's specialty pharmaceutical and medical-device distribution platform in mainland China. Rather than waiting for portfolio companies to build their own sales forces, CBC can plug acquisitions into R-Bridge's existing commercial infrastructure — accelerating revenue growth and providing a turnkey route to Chinese hospitals and clinics.